Why the study?
The rate of use and impact of antiplatelet pretreatment in patients with non-ST elevated acute coronary syndrome and its association with adverse events were not well established in Argentina.
Does pretreatment with P2Y12 inhibitors reduce in-hospital ischemic events in patients with NSTEACS?
Observational (n=1,297)
Yes
Does pretreatment with P2Y12 inhibitors reduce in-hospital ischemic events in patients with NSTEACS?
Pretreatment with P2Y12 inhibitors in NSTEACS patients did not reduce in-hospital ischemic events and showed a trend toward increased bleeding.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sigal et al. (2023) conducted an observational in Non-ST elevated acute coronary syndrome (NSTEACS) (n=1,297). Antiplatelet pretreatment vs. No pretreatment was evaluated on Composite of in-hospital death, myocardial infarction, stent thrombosis, post-MI angina, and transient ischemic event/cerebrovascular event (OR 1.4, 95% CI 0.89-2.3, p=0.13).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: